Inhalable Lactoferrin–Chondroitin Nanocomposites for Combined Delivery of Doxorubicin and Ellagic Acid to Lung Carcinoma

Elwakil, Mahmoud M. Abd; Mabrouk, Moustafa T.; Helmy, Maged W.; Abdelfattah, Elsayeda-Zeinab A.; Khiste, Sachin; Elkhodairy, Kadria A.; Elzoghby, Ahmed O.

doi:10.2217/nnm-2018-0039

Cited by 72 publications

(37 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To enhance their lung deposition, the nanocomplex was microencapsulated into mannitol microparticles. The resultant inhalable dry powder nanocomposites of the drug combination showed a significant reduction of the IC 50 value by 3.8-fold compared with the freely combined drug solution [22]. In another investigation, the herbal compound naringin was administered to lung through nebulized PLGA nanoparticles together with, celecoxib, the COX-2 inhibitor drug [32].…”

Section: Enhanced Localized Drug Deliverymentioning

confidence: 99%

“…Active targeting nanoparticles offer several pros including boosting drug selectivity to target cells and selective cytotoxicity to bypass side effects to normal cells, improvement of anticancer activity of the drug and its accumulation in cancer cells, and effectiveness in control of drug release [22].…”

Section: Enhanced Tumor Targetingmentioning

confidence: 99%

“…Therefore, microencapsulated nanoparticles (nanocomposites) possess dual advantages of enabling efficient aerosolization, deposition deeply in the lung, and effective tumor cells targeting (Figure 2). The herbal drug Ellagic acid (EA) was co-formulated with doxorubicin in the form of lactoferrin-chondroitin nanocomplex developed via electrostatic complexation [22]. EA was reported to delay drug resistance via inhibition of P-glycoprotein efflux pumps, allowing DOX to work efficiently.…”

Section: Enhanced Localized Drug Deliverymentioning

confidence: 99%

See 2 more Smart Citations

Nanomedicine-based approaches for improved delivery of phyto-therapeutics for cancer therapy

Hafez

Elkhodairy

Teleb

et al. 2020

Expert Opinion on Drug Delivery

View full text Add to dashboard Cite

Section: Enhanced Localized Drug Deliverymentioning

confidence: 99%

Section: Enhanced Tumor Targetingmentioning

confidence: 99%

Section: Enhanced Localized Drug Deliverymentioning

confidence: 99%

See 1 more Smart Citation

Nanomedicine-based approaches for improved delivery of phyto-therapeutics for cancer therapy

Hafez

Elkhodairy

Teleb

et al. 2020

Expert Opinion on Drug Delivery

View full text Add to dashboard Cite

“…The specific features of the carriers will be outlined and the achieved outcomes described. The envisaged applications of the nanocarriers in lung delivery are diverse, but particularly address the delivery of proteins or protein-based materials, either for local or systemic effect [39,40], cancer treatment [41,42] and local delivery of antibiotics [43,44]. Therefore, the review will specifically focus on these topics.…”

Section: Introductionmentioning

confidence: 99%

Multifunctional Nanocarriers for Lung Drug Delivery

Pontes

Grenha

2020

Nanomaterials

View full text Add to dashboard Cite

Nanocarriers have been increasingly proposed for lung drug delivery applications. The strategy of combining the intrinsic and more general advantages of the nanostructures with specificities that improve the therapeutic outcomes of particular clinical situations is frequent. These include the surface engineering of the carriers by means of altering the material structure (i.e., chemical modifications), the addition of specific ligands so that predefined targets are reached, or even the tuning of the carrier properties to respond to specific stimuli. The devised strategies are mainly directed at three distinct areas of lung drug delivery, encompassing the delivery of proteins and protein-based materials, either for local or systemic application, the delivery of antibiotics, and the delivery of anticancer drugs—the latter two comprising local delivery approaches. This review addresses the applications of nanocarriers aimed at lung drug delivery of active biological and pharmaceutical ingredients, focusing with particular interest on nanocarriers that exhibit multifunctional properties. A final section addresses the expectations regarding the future use of nanocarriers in the area.

show abstract

“…The formulation was evaluated for its in vitro cytoxicity against PC3 prostate carcinoma cells. The co-delivery of FLV, ALA and EA from NLC always provided better results in comparison with free drugs both when administered individually and mixed together, with significant differences in terms of cell survival, caspase-3 expression and incidence of apoptosis.In another interesting study, Abd Elwakil et al focused on the preparation of an inhalable spray-dried powder for targeted co-delivery of EA and doxorubicin (DOX) to lung carcinoma[92].This system consisted of nanocomposites comprised of drug-loaded NP and excipients like sugars just to reach the micro-range size necessary to ensure deposition in deep lung tissue. Once at the alveolar surface, the carbohydrate fraction rapidly dissolves, releasing the NP components apt to be exploited the polyelectrolyte electrostatic complexation.…”

mentioning

confidence: 99%

Formulation Strategies to Improve Oral Bioavailability of Ellagic Acid

Zuccari¹,

Baldassari²,

Ailuno³

et al. 2020

Preprint

View full text Add to dashboard Cite

Featured Application: An updated description of pursued approaches for efficiently resolving the low bioavailability issue of ellagic acid. Abstract: Ellagic acid, a polyphenolic compound present in fruits and berries, has recently been object of extensive research for its antioxidant activity, which might be useful for the prevention and treatment of cancer, cardiovascular pathologies, and neurodegenerative disorders. Its protective role justifies numerous attempts to include it in functional food preparations and in dietary supplements not only to limit the unpleasant collateral effects of chemotherapy. However, ellagic acid use as chemopreventive agent has been debated because of its poor bioavailability associated to low solubility, limited permeability, first pass effect, and interindividual variability in gut microbial transformations. To overcome these drawbacks, various strategies for oral administration including solid dispersions, micro-nanoparticles, inclusion complexes, selfemulsifying systems, polymorphs have been proposed. Here, we have listed an updated description of pursued micro/nanotechnological approaches focusing on the fabrication processes and the features of the obtained products, as well as on the positive results yielded by in vitro and in vivo studies in comparison to the raw material. The micro/nano-sized formulations here described might be exploited for pharmaceutical delivery of this active, as well as for the production of nutritional supplements or for the enrichment of novel foods.

show abstract

Inhalable Lactoferrin–Chondroitin Nanocomposites for Combined Delivery of Doxorubicin and Ellagic Acid to Lung Carcinoma

Abstract: Overall, inhalable lactoferrin-chondroitin sulfate nanocomposites would be a promising carrier for targeted drug delivery to lung cancer.

Cited by 72 publications

References 46 publications

Nanomedicine-based approaches for improved delivery of phyto-therapeutics for cancer therapy

Nanomedicine-based approaches for improved delivery of phyto-therapeutics for cancer therapy

Multifunctional Nanocarriers for Lung Drug Delivery

Formulation Strategies to Improve Oral Bioavailability of Ellagic Acid

Contact Info

Product

Resources

About